Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function.
about
Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrinsThe anti-angiogenic His/Pro-rich fragment of histidine-rich glycoprotein binds to endothelial cell heparan sulfate in a Zn2+-dependent mannerPathophysiology of heparan sulphate: many diseases, few drugsHeparin/heparan sulfate biosynthesis: processive formation of N-sulfated domainsFibroblast growth factors share binding sites in heparan sulphate.3-O-sulfated oligosaccharide structures are recognized by anti-heparan sulfate antibody HS4C3.Characterization of anti-heparan sulfate phage display antibodies AO4B08 and HS4E4.Screening for anticoagulant heparan sulfate octasaccharides and fine structure characterization using tandem mass spectrometryHeparan sulfate domain organization and sulfation modulate FGF-induced cell signalingHeparan sulfate differences in rheumatoid arthritis versus healthy seraBench-to-bedside review: the role of glycosaminoglycans in respiratory disease.Interactions between heparan sulfate and proteins: the concept of specificity.Method development and analysis of free HS and HS in proteoglycans from pre- and postmenopausal women: evidence for biosynthetic pathway changes in sulfotransferase and sulfatase enzymes.The 'sweet' and 'bitter' involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance.Regulation of endothelial cell functions by basement membrane- and arachidonic acid-derived products.Heparan sulfate biosynthesis: regulation and variability.Heparan sulfate in angiogenesis: a target for therapy.Isolation and characterization of low sulfated heparan sulfate sequences with affinity for lipoprotein lipase.VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase.Fibrillin-1 interactions with heparin. Implications for microfibril and elastic fiber assembly.Binding of endostatin to endothelial heparan sulphate shows a differential requirement for specific sulphates.Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use.Endostatin overexpression specifically in the lens and skin leads to cataract and ultrastructural alterations in basement membranes.Epac1 promotes melanoma metastasis via modification of heparan sulfate.The morphogenic properties of oligomeric endostatin are dependent on cell surface heparan sulfate.The heparin-binding site of antithrombin is crucial for antiangiogenic activityDefective N-sulfation of heparan sulfate proteoglycans limits PDGF-BB binding and pericyte recruitment in vascular development.N-terminal modification increases the stability of the recombinant human endostatin in vitro.A new model for the domain structure of heparan sulfate based on the novel specificity of K5 lyase.
P2860
Q24299560-93AC8F5A-3F62-4C0C-8CC0-6FB2944A8A84Q24302060-799339AF-893E-4375-92CA-A9E197EA40B8Q26823840-230B3AF8-25BB-442C-B1DC-65BBE346581DQ28280539-BC199DA5-0D07-457C-9D97-E7F4F0E6C21DQ31153852-956B5A87-7B86-4583-9CC2-4791793369A8Q33230192-63683445-5387-499E-A11D-93F23331F1FFQ33285352-CB1670D8-350E-4B2E-8994-BE73957C02E3Q33546538-7B461D87-4DC6-49CB-9463-9148B8C0F2EEQ33615579-35D49F7A-B517-4EA9-A398-1ABE94A44420Q35531571-7A531B03-F190-43DF-BC4E-477AEC527210Q35629808-481504F2-A1B2-4812-926B-DF202F8DD2FEQ36552851-169FA16F-5EF1-493B-AAE1-F46A533B4FAEQ37089817-28F60E43-5709-4380-A330-1307B274D3B8Q37346515-7FB02B75-8DEC-440C-87ED-92C5AE0EAEFCQ37787958-6F2010DF-3B26-4C72-A4BE-BA2125AA9178Q38050077-2F3B4A3C-A930-4E7B-AC52-54A9E1A82B2EQ38154506-8D215F54-6E2D-4654-9DAB-E72B485B441DQ38312237-1FEFE33B-B364-4EBB-82DA-93231335E173Q38319324-5B7BE9B9-C01D-4410-835A-16D81952C215Q38324440-3F830DCA-8F58-4FD5-9CF2-9B0F679A0894Q38353503-3148DEB2-E51C-4E5B-9C3E-065FAFAEF857Q38418286-DB1811AF-4CD1-425A-8FF6-B6AD3D7E871BQ38584966-92791486-1034-4D4C-B561-C4F8EB3AD656Q39549002-676CECA1-7DA2-433C-9349-4496B0586084Q40315779-2F5865B6-9F7F-49CE-B0D7-2C9B8D6193D8Q41845994-EB24A10B-19E8-4C26-9059-1C1B018B536CQ42276166-034193F0-13E8-425C-AE6D-137CE38C1117Q44456996-A135ACC7-0D96-4883-ABE1-85051E6EE6D0Q44816865-27F6ED7F-185B-4319-9AA4-FC53C30646B5
P2860
Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Role of heparan sulfate domain ...... of endothelial cell function.
@ast
Role of heparan sulfate domain ...... of endothelial cell function.
@en
Role of heparan sulfate domain ...... of endothelial cell function.
@nl
type
label
Role of heparan sulfate domain ...... of endothelial cell function.
@ast
Role of heparan sulfate domain ...... of endothelial cell function.
@en
Role of heparan sulfate domain ...... of endothelial cell function.
@nl
prefLabel
Role of heparan sulfate domain ...... of endothelial cell function.
@ast
Role of heparan sulfate domain ...... of endothelial cell function.
@en
Role of heparan sulfate domain ...... of endothelial cell function.
@nl
P2093
P2860
P356
P1433
P1476
Role of heparan sulfate domain ...... of endothelial cell function.
@en
P2093
Dorothe Spillmann
Johan Kreuger
Lena Claesson-Welsh
Maarten Vanwildemeersch
Rupert Timpl
Takako Sasaki
Taro Matsumoto
P2860
P304
P356
10.1093/EMBOJ/CDF638
P407
P50
P577
2002-12-01T00:00:00Z